[Venacorn or anavenol in the prevention of thromboembolic complications in pregnant women].
D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004929:Esculin / Q000627:therapeutic use*; D005026:Ethylene Glycols / Q000627:therapeutic use*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control*; D012431:Rutin / Q000627:therapeutic use*; D013923:Thromboembolism / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000188:drug therapy*; D014648:Varicose Veins / Q000150:complications
D004338:Drug Combinations; D005026:Ethylene Glycols; D005419:Flavonoids; D004088:Dihydroergotoxine; D004929:Esculin; D012431:Rutin; C005698:dihydroergotoxine mesylate, esculoside, rutoside drug combination; C032389:2-(2-naphthyloxy)ethanol
Venacorn (anavenol) w profilaktyce powikłań zakrzepowo-zatorowych u kobiet ciezarnych.